Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy

Table 5 Relationship between several markers and cancer caused death

	Cancer death (n)	Total (n)	Multivariate HR^a (95% CI)^{a, b}	Multivariate HR (95% CI) ^c
Tumor grade
High-middle	83	193	Reference	Reference
Low	35	57	1.43 (1.10 ~ 1.86)	1.41 (1.08 ~ 1.85)
Tumor stage
LD^a	57	143	Reference	Reference
ED^a	61	107	1.43 (1.10 ~ 1.85)	1.42 (1.09 ~ 1.84)
EGFR^a
Negative	90	202	Reference	Reference
Positive	28	48	1.31 (0.99 ~ 1.74)	1.30 (0.98 ~ 1.73)
KRAS^a
Negative	108	234	Reference	Reference
Positive	10	16	1.35 (0.90 ~ 2.03)	1.33 (0.88 ~ 2.01)
Serum PD-L1^a
<7.1 ng/ml	48	124	Reference	Reference
≥ 7.1 ng/ml	70	126	1.44 (1.09 ~ 1.88)	1.43 (1.08 ~ 1.87)
Tissue PD-L1
Negative	19	50	Reference	Reference
Positive	33	48	1.85 (1.24 ~ 2.75)	1.86 (1.24 ~ 2.76)

^aLD Limited disease, ED Extensive disease, EGFR Epidermal growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene, PD-L1 Programmed death ligand 1, HR Hazard ratio, CI Confidence interval
^bThe model was adjusted by age and gender
^cThe model was adjusted by age, gender, smoking history, performance status, tumor grade, tumor stage, tissue expressions of epidermal growth factor receptor and kirsten rat sarcoma viral oncogene

ISSN: 1465-993X